EE200300582A - IL-18 inhibiitorite kasutamine kesknärvisüsteemi kahjustuste raviks või ennetamiseks - Google Patents

IL-18 inhibiitorite kasutamine kesknärvisüsteemi kahjustuste raviks või ennetamiseks

Info

Publication number
EE200300582A
EE200300582A EEP200300582A EEP200300582A EE200300582A EE 200300582 A EE200300582 A EE 200300582A EE P200300582 A EEP200300582 A EE P200300582A EE P200300582 A EEP200300582 A EE P200300582A EE 200300582 A EE200300582 A EE 200300582A
Authority
EE
Estonia
Prior art keywords
inhibitors
treat
nervous system
central nervous
system damage
Prior art date
Application number
EEP200300582A
Other languages
English (en)
Inventor
Shohami Esther
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of EE200300582A publication Critical patent/EE200300582A/et
Publication of EE05263B1 publication Critical patent/EE05263B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EEP200300582A 2001-05-25 2002-05-23 IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks EE05263B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112067 2001-05-25
PCT/EP2002/005666 WO2002096456A1 (en) 2001-05-25 2002-05-23 Use of il-18 inhibitors for treating or preventing cns injuries

Publications (2)

Publication Number Publication Date
EE200300582A true EE200300582A (et) 2004-02-16
EE05263B1 EE05263B1 (et) 2010-02-15

Family

ID=8177454

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300582A EE05263B1 (et) 2001-05-25 2002-05-23 IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks

Country Status (30)

Country Link
US (1) US7655616B2 (et)
EP (1) EP1390070B1 (et)
JP (1) JP4344142B2 (et)
KR (1) KR20040030625A (et)
CN (1) CN1305529C (et)
AU (1) AU2002314103B2 (et)
BG (1) BG66395B1 (et)
BR (1) BR0210007A (et)
CA (1) CA2445664C (et)
CY (1) CY1119190T1 (et)
CZ (1) CZ307321B6 (et)
DK (1) DK1390070T3 (et)
EA (1) EA006744B1 (et)
EE (1) EE05263B1 (et)
ES (1) ES2617084T3 (et)
HK (1) HK1069762A1 (et)
HR (1) HRP20030842B1 (et)
HU (1) HU230294B1 (et)
IL (2) IL159014A0 (et)
LT (1) LT1390070T (et)
ME (1) ME00550B (et)
MX (1) MXPA03010743A (et)
NO (1) NO331882B1 (et)
PL (1) PL216228B1 (et)
PT (1) PT1390070T (et)
RS (1) RS56006B1 (et)
SK (1) SK288413B6 (et)
UA (1) UA80396C2 (et)
WO (1) WO2002096456A1 (et)
ZA (1) ZA200308172B (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101617A1 (en) 2003-05-13 2004-11-25 Applied Research Systems Ars Holding N.V. Active variants of the il-18 binding protein and medical uses thereof
EP2177907B1 (en) * 2004-06-30 2014-01-01 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use therefor
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
ES2376534T3 (es) * 2005-06-03 2012-03-14 Merck Serono Sa Uso de isoformas de il-18bp para el tratamiento y/o prevención de enfermedades inflamatorias neurológicas.
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
HUE055608T2 (hu) * 2013-09-05 2021-12-28 Ab2 Bio Sa IL-18-kötõ fehérje (IL-18BP) gyulladásos betegségekben
AU2016227644B2 (en) 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873453A (ja) * 1994-09-02 1996-03-19 Otsuka Pharmaceut Co Ltd サイトカイン阻害剤
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
EP1062210B1 (en) * 1998-03-09 2005-06-01 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1278540B1 (en) * 2000-05-05 2008-05-14 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
ES2227220T3 (es) * 2000-06-23 2005-04-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - inhibidor de factor de necrosis tumoral alfa y neuroprotector cerebral en traumatismo craneoencefalico cerrado.
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6671553B1 (en) * 2001-05-23 2003-12-30 Pacesetter, Inc. Implantable cardiac lead having terminating connector strain relief and method of manufacture

Also Published As

Publication number Publication date
PL367545A1 (en) 2005-02-21
CZ20033268A3 (en) 2004-07-14
ME00550B (me) 2011-10-10
UA80396C2 (en) 2007-09-25
JP2004534777A (ja) 2004-11-18
CA2445664C (en) 2012-03-06
WO2002096456A1 (en) 2002-12-05
ZA200308172B (en) 2004-10-21
PL216228B1 (pl) 2014-03-31
HRP20030842A2 (en) 2005-08-31
LT1390070T (lt) 2017-03-10
CN1305529C (zh) 2007-03-21
SK16032003A3 (sk) 2004-05-04
US7655616B2 (en) 2010-02-02
RS56006B1 (sr) 2017-09-29
EA200301299A1 (ru) 2004-04-29
EA006744B1 (ru) 2006-04-28
BG66395B1 (bg) 2013-12-31
CY1119190T1 (el) 2018-02-14
KR20040030625A (ko) 2004-04-09
CZ307321B6 (cs) 2018-06-06
CN1535160A (zh) 2004-10-06
EP1390070B1 (en) 2017-02-08
AU2002314103B8 (en) 2002-12-09
US20040191247A1 (en) 2004-09-30
EP1390070A1 (en) 2004-02-25
ES2617084T3 (es) 2017-06-15
HUP0304067A3 (en) 2006-01-30
NO331882B1 (no) 2012-04-23
IL159014A (en) 2012-05-31
JP4344142B2 (ja) 2009-10-14
SK288413B6 (sk) 2016-10-03
YU89403A (sh) 2006-05-25
PT1390070T (pt) 2017-03-01
DK1390070T3 (en) 2017-04-24
EE05263B1 (et) 2010-02-15
HU230294B1 (hu) 2015-12-28
BG108451A (en) 2005-02-28
CA2445664A1 (en) 2002-12-05
HK1069762A1 (en) 2005-06-03
NO20035160L (no) 2003-11-20
MXPA03010743A (es) 2004-03-02
NO20035160D0 (no) 2003-11-20
HUP0304067A2 (hu) 2004-03-29
HRP20030842B1 (hr) 2017-06-02
AU2002314103B2 (en) 2007-07-12
IL159014A0 (en) 2004-05-12
BR0210007A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
NO20050636L (no) Inhibitorer av tyrosinkinaser
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DE60232994D1 (de) Inhibitoren von mitotischem kinesin
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
DK1627639T3 (da) Anvendelse af COX-2-inhibitorer til behandling af affektive lidelser
IL149106A0 (en) Therapeutic use of selective pde10 inhibitors
HUP0300061A3 (en) Use of il-18 inhibitors
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
EE200300582A (et) IL-18 inhibiitorite kasutamine kesknärvisüsteemi kahjustuste raviks või ennetamiseks
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
SE0301854L (sv) Antiigensättningsbehandling

Legal Events

Date Code Title Description
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name